Autoimmune Diseases  >>  Actemra SC (tocilizumab SC)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actemra SC (tocilizumab SC) / Roche, Halozyme
NCT02534311: A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Completed
N/A
60
Europe
Tocilizumab, RoActemra
Hoffmann-La Roche
Rheumatoid Arthritis
12/15
12/15
NCT02552940: An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Completed
N/A
140
Europe
Tocilizumab, RoACTEMRA
Hoffmann-La Roche, nv Roche sa
Rheumatoid Arthritis
10/17
10/17
CONIFER, NCT03112213: Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment

Completed
N/A
135
Europe
Tocilizumab, RoACTEMRA®, NSAIDs
Hoffmann-La Roche
Rheumatoid Arthritis
07/18
07/18
NCT02648035: EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Completed
N/A
200
Europe
Tocilizumab, ACTEMRA
Hoffmann-La Roche
Rheumatoid Arthritis
12/18
12/18

Download Options